Meeting
2017 Gastrointestinal Cancers Symposium
TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.
Authors
Janet E. Murphy
Massachusetts General Hospital Cancer Center, Boston, MA
Janet E. Murphy , Jennifer Yon-Li Wo , Cristina Ferrone , Wenqing Jiang , Beow Y. Yeap , Lawrence Scott Blaszkowsky , Eunice Lee Kwak , Jill N. Allen , Jeffrey W. Clark , Jason Edward Faris , Andrew X. Zhu , Lipika Goyal , Harvey J. Mamon , Keith D Lillemoe , David P. Ryan , Thomas F. DeLaney , Carlos Fernandez-del Castillo , Yves Boucher , Theodore S. Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01821729
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 386)
DOI
10.1200/JCO.2017.35.4_suppl.386
Abstract #
386
Poster Bd #
H12
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.
First Author: Janet E. Murphy
Poster
2021 ASCO Annual Meeting
Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.
First Author: Andrew Oar
Poster
2017 Gastrointestinal Cancers Symposium
FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.
First Author: Janet E. Murphy
Poster
2016 Gastrointestinal Cancers Symposium
FOLFIRINOX for patients with borderline and never-resectable locally advanced pancreatic cancer, with the addition of chemoradiotherapy for potentially resectable patients: A phase II study.
First Author: Jon Kroll Bjerregaard